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Summary The p53 gene is one of the best studied tumour suppressor genes. Recently we performed mutation analysis on the p53 gene in a large number of bone and soft tissue sarcomas, and found that approximately one-third of the sarcomas have some type of DNA alteration at the p53 locus (Toguchida et al., 1992). However, the expression of the p53 protein resulting from these alterations still remains to be clarified. In this study, p53 expression in the sarcoma tissues was analysed immunohistochemically using antibody PAb421 (Oncogene Science) and its relationship to DNA alterations was examined. Of 113 tumours, 29 (25.7%) showed positive staining for the p53 protein. These included 19 of 67 osteosarcomas, five of 20 chondrosar-
comas, four of 11 malignant fibrous histiocytomas (MFHs) and one Ewing's sarcoma. In chondrosarcoma,
most of the p53-positive tumours belonged to highly malignant and atypical tumour types (dedifferentiated or mesenchymal type), suggesting a role for p53 mutation in the progression of cartilaginous tumours. All the
cases with a missense mutation showed strongly positive staining, while no immunoreactivity was observed in the remaining three-quarters with DNA alterations including gross rearrangement, frame-shift mutation,
nonsense mutation or mutation at splicing site except in one case. These results demonstrated the dominance of the p53 mutations with null protein expression in bone and soft tissue sarcomas, showing a unique characteristic of these types of tumours compared with other malignancies such as colon carcinomas.
The p53 gene, located on chromosome 17p, encodes a 53 kDa
nuclear phosphoprotein that has been studied extensively
(Levine et al., 1991). At first p53 was regarded as a tumour
antigen because the expression of this gene was observed in
SV40-transformed cells (Lane & Crawford, 1979) and the
co-transfection of the p53 gene with activated ras oncogene
was shown to transform primary rat embryo fibroblasts
(Parada et al., 1984). Later this gene was found to be a
tumour-suppressor because p53 with transforming ability was
proved to be mutated and reintroduction of a wild-type p53
gene into p53-deficient tumour cells can suppress the neo-
plastic phenotype (Finlay et al., 1989). Although the precise
biological function of p53 remains to be clarified, alterations
of the p53 gene have been observed in a variety of human
malignancies including sarcomas (Masuda et al., 1987; Nigro
et al., 1989; Stratton et al., 1990; Mulligan et al., 1990).
Recently, we reported the mutation spectrum of the p53 gene
in a large number of bone and soft tissue sarcomas, and
approximately one-third of sarcomas had some type of DNA
alteration (Toguchida et al., 1992). Of these alterations, one-
quarter was a missense mutation which was presumed to
produce a mutant p53 protein, and the remaining three-
quarters were other types of DNA alteration such as gross
rearrangements, frame-shifts, or nonsense mutations.
It has been reported that although the physiologic concen-
trations of wild type p53 protein in cells are immunohisto-
chemically undetectable, the increased concentration of the
mutated form due to an extended half-life is readily detect-
able (Rodrigues et al., 1990; Marks et al., 1991). However, it
is not clear whether all the cases with a missense mutation
show positive immunoreactivity. It also remains to be clari-
fied how p53 mutations other than missense mutation affect
protein expression.
In this study, we analysed immunoreactivity for the p53
protein in various types of bone and soft tissue sarcomas
using an antibody to the p53 protein to investigate the
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relationship between the expression status and DNA altera-
tions of the p53 gene.
Materials and methods
Tumoursamples
A total of 113 various types of bone and soft tissue sarcomas
were analysed. The histological diagnoses of these cases are
listed in Table I. Tumour tissue specimens were frozen imme-
diately after surgical removal and stored at -70°C.
Immunohistochemicalstaining
Frozen tissue specimens were embedded in OCT compound and cut into 6fim thick sections. They were then air-dried on
slides, fixed for 20 min in cold acetone and stored at - 70°C
until examination. At first, the slides were rinsed three times
in 0.01 M Phosphate-Buffered Saline (PBS), pH 7.2. Then, they were preincubated for 20min in 0.5% normal horse
serum diluted in PBS/5% foetal calf serum, followed by incubation with the primary antibody for I h at the concen-
tration of 10I gml-'. We used a monoclonal antibody PAb421 (Ab-1; Oncogene Science, Manhasset, NY) which
recognises a denaturation-resistant epitope located between
amino acids 370 and 378 of the p53 protein. This antibody is
considered to recognise both the wild-type and mutant forms
of the p53 protein. All incubations were performed in a
humidified chamber at room temperature. The endogenous peroxidase activity was blocked using 100% methanol con-
taining 0.3% hydrogen-peroxide. The binding of these
antibodies was visualised using the streptavidin-biotin immunoperoxidase system according to the manufacturer's
recommendations. After each incubation, the slides were
rinsed three times in PBS for 5 min. Peroxidase activity was
developed for 5 min with the enzyme substrate diaminoben-
zidine (0.5% diaminobenzidine in 0.05 M Tris buffer, pH 7.6-
0.6% hydrogen peroxide). The slides were then rinsed in
water and counterstained with Mayer's hematoxylin or
methyl green. For negative control slides, all these steps were
repeated, except for substituting the primary antibody by an
irrelevant, isotype-matched, monoclonal antibody or PBS. An osteosarcoma cell line, SaOS-2 which is known to lack the p53 gene and express no protein (Diller et al., 1990), is also
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Table I Expression of the p53 protein
Tumour type No. of % of positive Staining intensity
(no. of cases) positive cases cases (+) (+ +) (+ + +)
Osteosarcomaa (67) 19 28.4% 7 7 5
primary (54) 16 29.6% 7 6 3
metastasisb (21) 4 19.0% 0 2 2
Chondrosarcoma (20) 5 25.0% 1 0 4
MFHc (11) 4 36.4% 2 0 2
Leiomyosarcoma (3) 0 0.0%
Liposarcoma (3) 0 0.0%
ASPSc (2) 0 0.0%
Malignant lymphoma (2) 0 0.0%
Fibrosarcoma (2) 0 0.0%
Ewing's sarcoma (1) 1 100.0% 0 0 1
Neuroblastoma (1) 0 0.0%
Malignant schwannoma (1) 0 0.0%
Total (113) 29 25.7% 10 7 12
aBoth of primary and metastatic tumours of a same patient were analysed in eight
cases. bAll cases were lung-metastasis. cMFH: malignant fibrous histiocytoma, ASPS:
alveolar soft part sarcoma.
used as a negative control. As a positive control, we used an
osteosarcoma cell line HOS which has a missense mutation
and overexpresses the mutant p53 protein (Romano et al.,
1989).
Assessment ofthe results
Each slide was assessed without knowledge of the patients'
other data. Tissues. were scored as definitely negative (-),
weakly positive (+), intermediately positive (+ +) or strong-
ly positive (+ + +) according to the intensity of staining in
the nuclei of neoplastic cells, irrespective of the percentage of
positive cells. In addition, the percentage of positive cells was
also counted; 1: not more than 10% of the tumour cells were
stained. 2: 10-50% of the neoplastic cells were stained. 3:
more than 50% of the neoplastic cells were stained. The
staining was identified as positive only when the nuclei of
neoplastic cells were stained.
DNA analysis
In 95 of 113 cases, DNA abnormalities were analysed using
Southern blotting for gross rearrangements, PCR-Single
Strand Conformation Polymorphism (PCR-SSCP) analysis
and direct genomic sequencing for point mutations as pre-
viously described (Toguchida et al., 1992).
Results
Expression ofthe p53 gene
The results of immunohistochemical analysis are summarised
in Table I. Of the 113 tumours analysed, positive staining for
the p53 protein was observed in 29 cases (25.7%). The
percentage of positive neoplastic cells varied considerably
among cases; less than 10% of the neoplastic cells was
stained in four cases (13.8%), 10-50% in eight (27.6%) and
more than 50% in 17 (58.6%). The positive cells were ran-
domly distributed in a section in most cases, and immuno-
reaction was always located in the nucleus of the neoplastic
cells. As to the staining intensity, strongly positive staining
was detected in 12 (41.4%), intermediately in seven (24.1%),
and weakly in ten (34.5%) of these positive 29 cases.
Osteosarcoma Positive staining was observed in 19 of 67
cases (28.4%), (Table I). The frequency of the positive cases
in each subtype of tumour are; 10/41 (24.4%) in osteoblastic,
3/15 (20.0%) in chondroblastic, 0/1 (0%) in fibroblastic, 2/2
(100%) in telangiectatic, 1/3 (33.3%) in parosteal and 3/5
(60.0%) in other types. Twenty-one samples were taken from
metastatic lesions, and the frequency of p53 positive cases in
this group (4/21, 19.0%) showed no significant difference
from that of samples taken from the primary focus (16/54,
29.6%). In nine cases, tumour samples were available from
both primary and metastatic lesion of the same patient.
Analysis of these cases showed no difference in p53 expres-
sion between primary and metastatic lesions; one case with
positive staining for the p53 protein at the primary site also
expressed the p53 protein in the lung metastatic lesion, and
none ofeight cases without p53 expression at the primary site
demonstrated positive staining in the metastatic lesion.
Chondrosarcoma Five out of 20 cases (25.0%) showed
positive staining for the p53 protein (Table II). Among
positive cases, four were histologically high grade tumours
with strong staining intensity, and one case was a grade II
tumour with weak staining intensity. The difference in fre-
quency of p53 positive cases between histologically high
grade tumours (grade III, dedifferentiated or mesenchymal)
and low grade tumours (grade I or II) was statistically
significant (P = 0.0242). In one dedifferentiated chondrosar-
coma case (KS-182), specimens were taken from histologically
different portions within a tumour (original chondrosarco-
matous portion, fibrosarcomatous portion, or MFH-like por-
tion) and analysed separately. Although no immunoreactivity
was observed in samples from the former two portions, the
Table II Relationship between histological subtypes of chondrosarcoma and p53
expression
Histological subtypes No. of % of positive Staining intensity
(no. of cases) positive cases cases (+) (++) (+++)
Conventional (15)
Grade I (8) 0 0.0% 0 0 0
Grade II (6) 1 16.7% 1 0 0
Grade III (1) 0 0.0% 0 0 0
Dedifferentiated (3) 3 100.0% 0 0 3
Mesenchymal (2) 1 50.0% 0 0 11136 B. WADAYAMA et al.
Figure 1 Immunohistochemical detection of the p53 protein with
PAb421 in dedifferentiated chondrosarcoma (KS-182). This
tumour consisted of histologically different portions. Nuclear
staining of the p53 protein is not evident in fibrosarcomatous
portion a, but intensive nuclear staining is detected in tumour
cells of malignant fibrous histiocytoma (MFH)-like portion b.
Scale bar; lOtLm.
tumour cells in the MFH-like portion showed strong
immunoreactivity (Figure 1).
Other sarcomas Positive staining for the p53 protein was
observed in four of 11 malignant fibrous histiocytomas
(MFHs) (36.4%) and one Ewing's sarcoma, but the other
types of sarcomas (leiomyosarcoma, liposarcoma, alveolar
soft part sarcoma, malignant lymphoma, fibrosarcoma,
neuroblastoma and malignant schwannoma) showed no p53
expression (Table I).
Relationship between DNA abnormalities andprotein
expression
Mutations of the p53 gene were analysed at the DNA level in
95 of 113 cases, and 39 cases (41.1%) were found to have
genetic alterations at the p53 locus (Toguchida et al., 1992).
The relationship between abnormalities at the DNA level and
immunoreactivity of the p53 protein in each case is shown in
Table III. In all cases with a missense mutation, strongly or
intermediately positive staining was observed (Figure 2). In
the case of dedifferentiated chondrosarcoma with hetero-
geneous p53 expression within a tumour (KS-182), a missense
mutation was found in DNA from the p53-positive area, but
no DNA abnormalities were detected in specimens from the
p53-negative portions. No staining was evident in seven cases
with a nonsense or a frame-shift mutation (Figure 3), except
one case with one base pair deletion at codon 112 showing
intermediate immunoreactivity. Two cases with a base sub-
stitution at canonical splicing sites showed no immunoreac-
tivity for the p53 protein, and 20 of 21 cases with a gross
rearrangement of the p53 gene showed no detectable p53
protein. In the case with a rearrangement showing positive
staining, the structural change was heterozygous, and a
heterozygous missense mutation was also found in DNA
from the same tumour. Positive staining for the p53 protein
was also observed in 16 of 56 cases (28.6%) where no
abnormalities in the p53 gene were detected in DNA analysis,
although the staining intensity was weak in the majority of
the cases.
Discussion
The frequency of p53 positive cases in this study (25.7%) is
lower than that of two previous reports (Soini et al., 1992;
Dei Tos et al., 1993). Soini et al. reported that 13 out of 36
(36%) sarcomas showed p53-positive cells, and Dei Tos et al.
reported that p53 immunoreactivity was found in 26 out of
40 (65%) of malignant soft tissue tumours. The difference in
frequency may be due to the difference of the antibodies
used, and the use of several different antibodies may increase
the number of positive cases in our study. Alternatively, it
might be caused by the difference of types and numbers of
tumours in each study.
Our previous study demonstrated that approximately one-
third of bone and soft tissue sarcomas had some type of
DNA alterations at the p53 locus (Toguchida et al., 1992).
One-quarter of these mutations consisted of missense muta-
tions at conserved codons in the p53 gene which were pre-
sumed to produce a mutant-type p53 protein with an extend-
ed half-life. In agreement with this concept, all the tumours
with a missense mutation showed positive staining for the
p53 protein with relatively strong intensity, although there
was a variation in the percentage of positive cells within a
tumour. This may be the result of mutational heterogeneity
within a tumour or, more likely, due to the different cell-cycle
stage of each tumour cell because the immunoreactivity of
the p53 protein has been shown to change during the cell-
cycle (M0rkve et al., 1991).
We found that 16 of 56 cases with no apparent DNA
alteration at the p53 locus showed weak but positive staining
for the p53 protein. These tumours may possess some types
of mutations, especially missense mutations, which failed to
be detected in the initial screening of PCR-SSCP analysis, or
were located outside of the analysed regions. However,
Western blot analysis of some of these cases showed that the
band at 53 kDa detected by PAb421 which recognised both
wild and mutant p53, was unable to be detected by a mutant-
specific antibody (PAb240, Oncogene Science), (data not
shown). This result suggests that the expressed protein is not
mutant but wild-type. Wild-type p53 protein, but niot mutant
forms, binds to SV40 large T antigen and is overexpressed in
SV40-transformed cells (Levine et al., 1991). Binding to a
cellular homologue, such as MDM2 (Oliner et al., 1992) may
cause similar overexpression of the wild-type p53.
All tumours with point mutations other than missense
mutations, which were predicted to produce no intact p53
protein due to a premature termination codon or abnormal
splicing showed negative staining for the p53 protein except
one case with one base deletion at codon 112 (KS-131). This
frame-shift mutation is predicted to create a premature stop
codon downstream at codon 122. However, it might create a
new splicing site and produce a mutant p53 protein that can
be recognised by the antibody used in this study.
A high frequency of gross rearrangement is one of the
unique characteristics of the p53 gene mutations in osteosar-
comas (Masuda et al., 1987; Miller et al., 1990). Because
most of these rearrangements take place in intron 1 after the
noncoding exon 1, and no structural change was found in the
coding region of the p53 gene (Masuda et al., 1987; Miller et
al., 1990), it was unclear how these mutations affect proteinP53 EXPRESSION IN BONE AND SOFT TISSUE SARCOMAS 1137
Table III Relationship between DNA abnormalities and protein expression of the
p53 gene in sarcomas
Mutation
ID no. Tumour type Exon Codon Changea Immunoreactivity
Point mutations
Missense 10/10 (100.0%)b
KS-57 Chondrosarcoma 5 162 Ile-Phe + ++ /3C
KS-93 Chondrosarcoma 5 173 Val-Ala + + +/3
KS-134 Osteosarcoma 6 193 His-Gln + +/3
KS-182 Chondrosarcoma 7 249 Arg-Thr + + +/3
KS-154 Osteosarcoma 7 250 Pro-Leu ++ +/1
KS-96 MFHd 8 273 Arg-His + + +/3
KS-241 Osteosarcoma 8 273 Arg-His + + +/2
KS-81 Osteosarcoma 8 281 Asp-His + + +/3
KS-103 Osteosarcoma 8 281 Asp-Asn + + +/3
KS-236 Osteosarcoma 8 281 Asp-Glu + +/2
Nonesense or frame-shift 1/7 (14.3%)
KS-146 Osteosarcoma 4 46-7 lbp dele -
KS-131 Osteosarcoma 4 112 lbp del ++/3
KS-133 MFH 6 196 Arg-stop -
KS-254 Osteosarcoma 6 215-8 1lbp del -
KS-211 Osteosarcoma 6 221 Glu-stop -
KS-140 Osteosarcoma 7 227-8 4bp del
KS-39 Chondrosarcoma 9 316-7 lbp ins
Splicing site 0/2 (0.0%)
KS-197 Osteosarcoma 9 splice
acceptor
site
KS-107 Liposarcoma 9 splice
donor
site
Rearrangements 1/21 (4.8%)
aContains both amino acid change and nucleotide change. bPositive case/total case
(percentage). cIntensity/frequency. Intensity: + + +/strong; + +/intermediate,
+/weak. Frequency: 1/ less than 10%, 2/ 10-50%, 3/ more than 50% of the
neoplastic cells were stained. dMFH: malignant fibrous histiocytoma. elbp del: 1 base
pair deletion.
a
1 2 3 A G C T A G C T
G
G
C
A
Control KS-236
Figure 2 Osteosarcoma (unclassified, MFH-like type) (KS- 236) with a missense point mutation. a, PCR-SSCP analysis at exon 8
of the p53 gene. Abnormal band with slower mobility is recognised at lane 3 (lane 1, 2 are normal controls). b, Direct genomic
sequencing of exon 8. Homozygous C to G transversion was detected at codon 281 substituting Glu for Asp. c, Immunohisto-
chemical analysis of the tumour tissue. Nuclear staining is evident in tumour cells. Scale bar; 10 gm.
b
G
G
C
A1138 B. WADAYAMA et al.
a
1 2 3
b
A G C T A G C T
T T
C C
C C
G C
CG C T
G G
G T
T G
A G
T T
C G
C T
C G
G A
T
A
KS-254 Control
Figure 3 Osteosarcoma (chondroblastic type) (KS-254) with a frame-shift mutation. a, PCR-SSCP analysis at exon 6. Abnormal
band with faster mobility is recognised at lane 2. (1, 3 lanes are normal controls). b, Direct genomic sequencing of exon 6.
Heterozygous 11 base pair delection spanning from codon 215 to 218 was detected. c, Immunohistochemical analysis. No positive
staining is observed in tumour cells. Scale bar; 10 gm.
expression. In this study, none of 21 cases with a rearrange-
ment expressed the p53 protein except one case with a heter-
ozygous abnormality in which a heterozygous missense
mutation was also found. Therefore, our results indicate that
the gross rearrangement of the p53 gene in osteosarcomas
will not lead to expression of the p53 protein.
In summary, we found that three-quarters of the p53
mutations in sarcomas led to no expression of the protein,
which was in contrast with other cancers such as colon
carcinomas where more than 90% of the mutations were
shown to produce mutant p53 protein (Baker et al., 1990),
suggesting that the dominant-negative effect of the mutant
p53 protein may not be mandatory in the development of
sarcomas.
Mutation of the p53 gene is reported to be associated with
tumour progression and poor prognosis in some types of
human cancers (Baker et al., 1990; Fults et al., 1992; Mazars
et al., 1992; Sameshima et al., 1992; Fujimoto et al., 1992).
Among many types of bone and soft tissue sarcomas, chon-
drosarcoma is one of the tumours with a clear histological
grading, and the clinical prognosis has been shown to be
closely associated with this classification (Hearley & Lane,
1986). In this study, mutations of the p53 gene were found
mostly in a high grade tumours (grade III) or atypical chon-
drosarcomas such as dedifferentiated or mesenchymal types.
Dedifferentiated chondrosarcoma is known to be highly
malignant with an ominous prognosis (Capanna et al., 1988)
and the prognosis of patients with mesenchymal chondrosar-
coma is also rather poor (Nakashima et al., 1986). These
results suggest a role for p53 gene mutation in the progres-
sion of chondrosarcoma. The result showing mutational
heterogeneity in one dedifferentiated chondrosarcoma case
(KS-182) further suggests the importance of the p53 gene in
the regulation of differentiation. We have established a
tumour cell line from dedifferentiated chondrosarcoma with a
missense p53 mutation (Toguchida & Yamaguchi, unpublish-
ed data), and it would be intriguing to investigate whether
the expression of differentiation markers of chondrosarcoma,
such as the type II collagen gene (Benya & Shaffer, 1982),
would be restored by reintroduction of the wild-type p53
gene into these dedifferentiated tumours.
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